
    
      This is an open-label, multicenter study designed to evaluate efficacy and safety of reducing
      daily oral corticosteroid (OCS) use after initiation of 30 mg dose of benralizumab
      administered subcutaneously (SC) in patients with severe eosinophilic asthma receiving
      high-dose inhaled corticosteroid (ICS)/long-acting Î²2 agonist (LABA) and OCS with or without
      additional asthma controller(s).
    
  